Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.
Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the utility of docetaxel in metastatic castration-sensitive prostate cancer (mCSPC).
Two trials examined docetaxel in the mCSPC space: CHAARTED and STAMPEDE, says Hwang. The multiarm, phase 3 STAMPEDE trial examined the addition of up-front abiraterone acetate (Zytiga) or doctaxel to androgen deprivation therapy (ADT). The study was conducted in the United Kingdom and has answered several questions in this space, says Hwang. In the CHAARTED study, investigators wanted to see whether concomitant treatment of docetaxel with ADT would result in longer overall survival than ADT alone. Both trials showed that docetaxel improved survival for patients with mCSPC, says Hwang.
Data with abiraterone acetate were also reported; results from STAMPEDE and the LATITUDE trial showed that the addition of abiraterone to standard of care, which at the time was ADT, also improved survival in this patient population, concludes Hwang.